COMMUNIQUÉS West-GlobeNewswire

Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20/05/2024 - 14:00

SOUTH SAN FRANCISCO, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that the Human Capital Committee of its Board of Directors, which is composed [...]

PetMed Express, Inc. Announces Appointment of Justin Mennen to Board of Directors

20/05/2024 - 14:00

Veteran technology executive brings decades of experience leading digital transformations across large-scale global enterprises DELRAY BEACH, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. , parent company [...]

Intercept Presents New Sub-Analyses of Phase 3 POISE Data Showcasing the Effect of OCA on Key Liver Biomarkers and Fibrosis in Patients with PBC at Digestive Disease Week® 2024

20/05/2024 - 14:00

OCA normalizes levels of ALT and AST, liver biomarkers associated with poor clinical outcomes in a significantly higher proportion of patients after 12 months of treatment compared to placebo; reductions demonstrated as [...]

Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024

20/05/2024 - 14:00

Four clinical device performance studies successfully demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions and eating schedules SAN DIEGO, May 20, 2024 ( [...]

GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors

20/05/2024 - 14:00

GIGA-564 is a differentiated anti-CTLA-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with CTLA-4 blockade Researchers from the National Cancer Institute will [...]

Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention

20/05/2024 - 14:00

BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- Cerevance , a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced that Craig Thompson, chief executive officer, will [...]

Volta Medical presents results from the first transatlantic randomized controlled trial comparing AI-assisted ablation procedure with the conventional treatment for persistent atrial fibrillation patients

20/05/2024 - 14:00

TAILORED-AF trial findings demonstrated superiority in freedom from atrial fibrillation (AF) with or without anti-arrhythmic drugs at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) [...]

CervoMed to Appoint William Elder as Chief Financial Officer

20/05/2024 - 14:00

BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) [...]

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

20/05/2024 - 13:59

Long-term chronic fatigue syndrome (CFS) symptoms can be triggered by certain prior acute infections Prominent researchers/clinicians in the tick-borne disease scientific community postulate that latent Babesia spp [...]

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

20/05/2024 - 13:58

CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (“Foghorn”) (Nasdaq: FHTX) today announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of [...]

BrightSpring Health Services Announces Onco360® Was Selected as National Pharmacy Partner for OJEMDA™

20/05/2024 - 13:30

LOUISVILLE, Ky., May 20, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that its company, Onco360 ® , one of the nation’s largest [...]

Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders

20/05/2024 - 13:30

Reunion’s lead asset, RE104, is a potential best-in-class, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy to provide lasting benefits to patients with [...]

Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June

20/05/2024 - 13:03

-- Researchers to Present New Phase 2 Data Showing Safety and Anti-Leukemic Activity with WU-CART-007 and Additional New Findings for this Investigational, Off-the-Shelf Allogeneic CAR-T Cell Therapy -- Company to [...]

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

20/05/2024 - 13:00

MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and [...]

Aveanna to Participate at the UBS Healthcare Services Cape Cod Summit and Jefferies Global Healthcare Conference

20/05/2024 - 13:00

ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the UBS Healthcare Services Cape Cod Summit in Chatham, MA on [...]

Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

20/05/2024 - 13:00

New production process will be developed based on Pluri’s proprietary 3D cell expansion technology Human breast milk oligosaccharides are known to shape the gut microbiota and thus provide health benefits to adults [...]

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference

20/05/2024 - 13:00

Presentations highlight new VCIEL scale to measure small intestinal mucosal health and research from rich database of latiglutenase Phase 2 clinical trials BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero [...]

At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes

20/05/2024 - 13:00

Arecor Therapeutics plc (“Arecor” or “the Company”) AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES AT278 [...]

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

20/05/2024 - 13:00

Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO ® in China, Hong Kong, Macau, [...]